Form 4 for GRCE Grace Therapeutics, Inc.

Accepted 2026-09-23 18:19:25 ET · period of report 2026-09-21 · accession 0001493152-26-043996 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
MI	2026-09-23 18:19	2026-09-21+	GRCE	Opaleye Management Inc.	10%	P - Purchase	$2.10	+15.1K	2.86M	+0.5%	+$31.7K

Every reported transaction

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock, par value $0.0001 per share	2026-09-21	P	A	9,771	$2.10	2,850,000	I By Opaleye, L.P.	—	—	(F1) Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management, Inc. may be deemed to beneficially own the securities owned directly by the Fund. (F2) Opaleye Management, Inc. disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Opaleye Management, Inc. is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or for any other purpose.
2	Common	Common Stock, par value $0.0001 per share	2026-09-23	P	A	5,318	$2.10	2,855,318	I By Opaleye, L.P.	—	—	(F1) Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management, Inc. may be deemed to beneficially own the securities owned directly by the Fund. (F2) Opaleye Management, Inc. disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Opaleye Management, Inc. is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or for any other purpose.